Aurinia Pharmaceuticals (NASDAQ:AUPH) Releases Quarterly Earnings Results, Meets Estimates

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) released its quarterly earnings data on Thursday. The biotechnology company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01, Briefing.com reports. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.75%. The business had revenue of $57.10 million during the quarter, compared to analyst estimates of $54.25 million. During the same period last year, the business earned ($0.08) EPS. Aurinia Pharmaceuticals’s revenue was up 37.6% compared to the same quarter last year.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH traded down $0.11 during midday trading on Friday, reaching $5.50. 2,032,563 shares of the company’s stock traded hands, compared to its average volume of 1,420,359. The company has a fifty day simple moving average of $5.52 and a two-hundred day simple moving average of $5.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.05 and a current ratio of 5.60. The company has a market cap of $786.61 million, a P/E ratio of -12.79 and a beta of 1.44. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $11.15.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.